| abstract |
The present invention relates to a combination comprising an HSV-1 and HSV-2 binding monoclonal antibody or fragment thereof and an antiviral agent, and a pharmaceutical formulation comprising said combination, optionally together with a pharmaceutically acceptable excipient And prevention and / or treatment of genital herpes, HSV gingival stomatitis, and recurrent cold sores, herpes simplex encephalitis (HSE), neonatal HSV, HSV disease in immunocompromised hosts, and herpesvirus infections including HSV keratitis or keratoconjunctivitis And its use in [Selection] Figure 1 |